Kymera Therapeutics (NASDAQ:KYMR) Director Sells $530,764.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 5,900 shares of Kymera Therapeutics stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $89.96, for a total value of $530,764.00. Following the completion of the transaction, the director directly owned 5,641 shares of the company’s stock, valued at approximately $507,464.36. This trade represents a 51.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Wednesday, April 22nd, Bruce Booth sold 100 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.08, for a total value of $9,008.00.
• On Wednesday, April 15th, Bruce Booth sold 3,135 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.10, for a total value of $282,463.50.
• On Wednesday, April 15th, Bruce Booth sold 2,200 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.95, for a total value of $197,890.00.
• On Tuesday, April 14th, Bruce Booth sold 4,159 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.97, for a total value of $374,185.23.
• On Monday, March 2nd, Bruce Booth sold 81,866 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.13, for a total value of $7,378,582.58.

Kymera Therapeutics Price Performance

Shares of KYMR traded down $2.26 during trading hours on Friday, hitting $84.91. The stock had a trading volume of 393,678 shares, compared to its average volume of 710,755. The firm has a 50 day simple moving average of $84.58 and a 200-day simple moving average of $75.31. The firm has a market capitalization of $6.93 billion, a P/E ratio of -23.07 and a beta of 2.28. Kymera Therapeutics, Inc. has a 1-year low of $28.06 and a 1-year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The firm had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business’s quarterly revenue was down 60.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.88) earnings per share. Equities analysts predict that Kymera Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Keudell Morrison Wealth Management boosted its stake in shares of Kymera Therapeutics by 5.9% in the 1st quarter. Keudell Morrison Wealth Management now owns 6,990 shares of the company’s stock worth $582,000 after buying an additional 390 shares during the last quarter. Rockefeller Capital Management L.P. boosted its stake in shares of Kymera Therapeutics by 21,538.1% in the 4th quarter. Rockefeller Capital Management L.P. now owns 25,533 shares of the company’s stock worth $1,987,000 after buying an additional 25,415 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Kymera Therapeutics in the 4th quarter worth approximately $198,000. Virtu Financial LLC purchased a new position in shares of Kymera Therapeutics in the 4th quarter worth approximately $2,123,000. Finally, T. Rowe Price Investment Management Inc. boosted its stake in shares of Kymera Therapeutics by 3.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 629,745 shares of the company’s stock worth $49,001,000 after buying an additional 18,524 shares during the last quarter.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Tuesday. Barclays raised their target price on Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research note on Tuesday, January 27th. Piper Sandler lifted their price target on Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. UBS Group lifted their price target on Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Finally, Jefferies Financial Group initiated coverage on Kymera Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $110.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $118.90.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.